Study Details:

This study checks how safe and effective the drug upadacitinib is for adults with Systemic Lupus Erythematosus (SLE), a disease that causes inflammation in the body. Upadacitinib is already used for other diseases like rheumatoid arthritis. In this study, some participants will get the real drug and others will get a placebo (a pill with no medicine) to compare the effects.

The study is "double-blinded," meaning neither the participants nor the doctors know who gets the real drug. It's divided into three parts. In parts 1 and 2, people are randomly put into groups to get either the drug or placebo for 52 weeks, and part 3 follows after that.

• Participation involves taking a pill daily for up to 104 weeks and regular hospital visits.
• There may be more treatment tasks than usual care, like tests and questionnaires.
• 500 participants are needed for parts 1 and 2 in about 320 locations worldwide.

Before joining, participants need to meet certain health conditions and can't have certain other diseases, be pregnant, or plan surgeries during the study.